Health Economics


This section of the ESCEO web site, devoted to health economics, will provide, on a regular basis, expert opinion, consensus statements and reprints of papers that either are produced by members of our Scientific Committee or that members of our Scientific Committee found of particular interest to the ESCEO members. The scope includes cost-effectiveness of interventions and the burden of disease from an economic perspective. Our objective is to provide you with clear and up-to-date, scientifically reliable information dealing with topics that are directly linked with the goals and missions of ESCEO.

 

Publications


DOWNLOADTITLEAUTHORS
Health Technology Assessment in OsteoporosisM. Hiligsmann, J.A. Kanis, J. Compston, C. Cooper, B. Flamion, P; Bergmann, J.-J. Body, S. Boonen, O. Bruyère, J.-P. Devogelaer, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster
Incidence and socioeconomic burden of hip fractures in Italy: extension study 2003-2005P. Piscitelli, M.L. Brandi, U. Tarantino, A. Baggiani, A. Distante, M. Muratore, V. Grattagliano, A. Migliore, M. Granata, G. Guglielmi, R. Gimigliano, G. Iolascon
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosisB. Jönsson, O. Ström, J. A. Eisman, A. Papaioannou, E. S. Siris, A. Tosteson, J. A. Kanis.
Validation of the IOF quality of life questionnaire for patients with wrist fractureP. Lips, K. Jameson, M. L. Bianchi, S. Goemaere, S. Boonen, J. Reeve, J. Stepan, O. Johnell, N. M. van Schoor, E. Dennison, J. A. Kanis, C. Cooper, Working Group for Quality of Life of the International Osteoporosis Foundation.
FRAX® and its applications in health economics - Cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an exampleO. Ström, F. Borgström, M. Kleman, E. McCloskey, A. Odén, H. Johansson, J.A. Kanis.
Osteoporosis: burden, health care provision and opportunities in the EUO. Ström, F. Borgström, J. A. Kanis, J. Compston, C. Cooper, E. V. McCloskey, B. Jönsson.
An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal womenJ. A. Kanis, E. V. McCloskey, B. Jonsson, A. Cooper, O. Ström, F. Borgström
The cost-effectiveness of alendronate in the management of osteoporosisJ. A. Kanis, J. Adams, F. Borgström, C. Cooper, Bengt Jönsson, D. Preedy, P. Selby, J. Compston.
Reply to Letter to the Editor: Modelling cost-effectiveness in osteoporosisJ. A. Kanis, J. Adams, F. Borgström, C. Cooper, Bengt Jönsson, D. Preedy, P. Selby, J. Compston.
An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish settingF. Borgström, B. Jönsson, O. Ström, J. A. Kanis
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspectiveF. Borgström . Å. Carlsson . H. Sintonen . S. Boonen . P. Haentjens . R. Burge . O. Johnell . B. Jönsson . J. A. Kanis
At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosisF. Borgström; O. Johnell, J. A. Kanis, B. Jönsson, C. Rehnberg
Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomized controlled trialN. Zethraeus, F. Borgström, B. Jönsson, J. A. Kanis
Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK - Results based on the Women's Health Initiative randomised controlled trialI. Lekander, F. Borgström, O. Ström, N. Zethraeus, J. A. Kanis
Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UKI. Lekander, F. Borgström, O. Ström, N. Zethraeus, J. A. Kanis
Glucocorticoid-induced osteoporosis: a systematic review and cost - utility analysisJ. A. Kanis, JE. Brazier, MD. Stevenson, E.V. McCloskey, S. Davis, M. Lloyd-Jones
Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in womenMD. Stevenson, JE Brazier, NW Calvert, M. Lloyd-Jones, JE Oakley, J. A. Kanis
Incorporating adherence into health economic modelling of osteoporosisO. Ström, F. Borgström, J. A. Kanis, B. Jönsson
Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference modelN. Zethraeus, F. Borgström, O. Ström, J. A. Kanis, B. Jönsson
The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture RisksT.-P. van Staa, J. A. Kanis, P. Geusens, A. Boonen, H. G. M. Leufkens, C. Cooper
Utility Values Associated with Osteoporotic Fracture: A Systematic Review of the LiteratureM. Hiligsmann, O. Ethgen, F. Richy, J.-Y. Reginster
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis MedicationsM. Hiligsmann, V. Rabenda, H.-J. Gathon, O. Ethgen, J.-Y. Reginster
Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in OsteoporosisM. Hiligsmann, O. Ethgen, O. Bruyere, F. Richy, H.-J. Gathon, J.-Y. Reginster
An Economic Evaluation of Quantitative Ultrasonometry as Pre-Screening Test for the Identification of Patients with OsteoporosisM. Hiligsmann, O. Ethgen, O. Bruyere, J.-Y. Reginster
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 yearsM. Hiligsmann, O. Bruyere, J.-Y. Reginster
Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic womenM. Hiligsmann, O. Bruyere, J.-Y. Reginster
The need for economic evaluation in osteoarthritisO. Bruyere, J.-Y. Reginster
Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysisO. Bruyere, S. Scholtissen, A. Neuprez, M. Hiligsmann, A. Toukouki, J.-Y. Reginster
The risk and burden of vertebral fractures in SwedenJ.A. Kanis, O. Johnell, A. Oden, F. Borgstrom, N. Zethraeus, C. De Laet, B. Jonsson
The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patientsM. Hiligsmann, V. Rabenda, O. Bruyere, J.-Y. Reginster
Cost-Effectiveness of Osteoporosis Screening Followed by Treatment: The Impact of Medication AdherenceM. Hiligsmann, H.-J. Gathon, O. Bruyere, O. Ethgen, V. Rabenda, J.-Y. Reginster
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX®F. Borgström, O. Ström, J. Coelho, H. Johansson, A. Oden, E. V. McCloskey, J. A. Kanis
The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosisF. Borgström, O. Ström, J. Coelho, H. Johansson, A. Oden, E. V. McCloskey, J. A. Kanis

 


JOURNAL

Aging clinical and experimental research offers a multidisciplinary forum on the progressing field of gerontology and geriatrics. The areas covered by the journal include: biogerontology, neurosciences, epidemiology, clinical gerontology and geriatric assessment, social, economical and behavioral gerontology. “Aging clinical and experimental research” appears bimonthly and publishes review articles, original papers and case reports.

Discover the official journal of ESCEO on Springer.com and read the journal contents on Springerlink.com.
You can get the table of contents of every new issue published in Aging Clinical and Experimental Research. Sign up for the ToC Alert for this journal with your e-mail address. It’s easy and it’s free.